Compare BBW & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBW | LRMR |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.3M | 455.8M |
| IPO Year | 2004 | 2014 |
| Metric | BBW | LRMR |
|---|---|---|
| Price | $33.06 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $67.71 | $16.50 |
| AVG Volume (30 Days) | 346.5K | ★ 1.7M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | ★ 3.99 | N/A |
| Revenue | ★ $357,866,000.00 | N/A |
| Revenue This Year | $5.63 | N/A |
| Revenue Next Year | $4.62 | $1,816.14 |
| P/E Ratio | $8.51 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.96 | $2.26 |
| 52 Week High | $75.77 | $6.42 |
| Indicator | BBW | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 30.91 |
| Support Level | N/A | $2.72 |
| Resistance Level | $39.83 | $3.74 |
| Average True Range (ATR) | 2.00 | 0.18 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 3.37 | 8.66 |
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments: Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, U.K., Ireland, and two e-commerce sites, the international franchising segment includes royalties and product and fixture sales from other international operations under franchise agreements, and the commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.